Current Status of Research on the Mechanisms of Tumor-associated Macrophages in Esophageal Cancer Progression

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Dec 16

PMID 39678502

Authors

Yuchao Tang

Tingting Shi

Shu Lin

Taiyong Fang

Affiliations

Soon will be listed here.

Abstract

Esophageal carcinoma (EC) is one of the most common tumors in China and seriously affects patient survival and quality of life. In recent years, increasing studies have shown that the tumor microenvironment is crucial in promoting tumor progression and metastasis. Tumor-associated macrophages (TAM) are key components of the tumor immune microenvironment and promote both tumor growth and antitumor immunity. Much evidence suggests that TAMs are closely associated with esophageal tumors. However, understanding of the clinical value and mechanism of action of TAM in esophageal cancer remains limited. Therefore, we reviewed the status of research on the role and mechanism of action of TAM in EC progression and summarized its potential clinical application value to provide a theoretical basis for the clinical treatment of EC.

References

Zhu X, Liang R, Lan T, Ding D, Huang S, Shao J . Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer. J Immunother Cancer. 2022; 10(9). PMC: 9476138. DOI: 10.1136/jitc-2021-004219. View

Tanigawa K, Tsukamoto S, Koma Y, Kitamura Y, Urakami S, Shimizu M . S100A8/A9 Induced by Interaction with Macrophages in Esophageal Squamous Cell Carcinoma Promotes the Migration and Invasion of Cancer Cells via Akt and p38 MAPK Pathways. Am J Pathol. 2021; 192(3):536-552. DOI: 10.1016/j.ajpath.2021.12.002. View

Zhou J, Zheng S, Liu T, Liu Q, Chen Y, Ma R . Infiltrated M2 tumour-associated macrophages in the stroma promote metastasis and poor survival in oesophageal squamous cell carcinoma. Histol Histopathol. 2018; 34(5):563-572. DOI: 10.14670/HH-18-061. View

Baba Y, Nomoto D, Okadome K, Ishimoto T, Iwatsuki M, Miyamoto Y . Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma. Cancer Sci. 2020; 111(9):3132-3141. PMC: 7469863. DOI: 10.1111/cas.14541. View

Cianciaruso C, Beltraminelli T, Duval F, Nassiri S, Hamelin R, Mozes A . Molecular Profiling and Functional Analysis of Macrophage-Derived Tumor Extracellular Vesicles. Cell Rep. 2019; 27(10):3062-3080.e11. PMC: 6581796. DOI: 10.1016/j.celrep.2019.05.008. View

Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N . The cancer metabolic reprogramming and immune response. Mol Cancer. 2021; 20(1):28. PMC: 7863491. DOI: 10.1186/s12943-021-01316-8. View

Zhang S, Zhang S, Ma X, Zhan J, Pan C, Zhang H . Intratumoral microbiome impacts immune infiltrates in tumor microenvironment and predicts prognosis in esophageal squamous cell carcinoma patients. Front Cell Infect Microbiol. 2023; 13:1165790. PMC: 10174428. DOI: 10.3389/fcimb.2023.1165790. View

Lu Z, Zheng S, Liu C, Wang X, Zhang G, Wang F . S100A7 as a potential diagnostic and prognostic biomarker of esophageal squamous cell carcinoma promotes M2 macrophage infiltration and angiogenesis. Clin Transl Med. 2021; 11(7):e459. PMC: 8265170. DOI: 10.1002/ctm2.459. View

Lu Y, Guo L, Ding G . PD1 tumor associated macrophages predict poor prognosis of locally advanced esophageal squamous cell carcinoma. Future Oncol. 2019; 15(35):4019-4030. DOI: 10.2217/fon-2019-0519. View

10.

Zhao X, Qu J, Sun Y, Wang J, Liu X, Wang F . Prognostic significance of tumor-associated macrophages in breast cancer: a meta-analysis of the literature. Oncotarget. 2017; 8(18):30576-30586. PMC: 5444766. DOI: 10.18632/oncotarget.15736. View

11.

Gunassekaran G, Vadevoo S, Baek M, Lee B . M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials. 2021; 278:121137. DOI: 10.1016/j.biomaterials.2021.121137. View

12.

Wang H, Tian T, Zhang J . Tumor-Associated Macrophages (TAMs) in Colorectal Cancer (CRC): From Mechanism to Therapy and Prognosis. Int J Mol Sci. 2021; 22(16). PMC: 8395168. DOI: 10.3390/ijms22168470. View

13.

Roszer T . Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms. Mediators Inflamm. 2015; 2015:816460. PMC: 4452191. DOI: 10.1155/2015/816460. View

14.

Gao J, Liang Y, Wang L . Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy. Front Immunol. 2022; 13:888713. PMC: 9280632. DOI: 10.3389/fimmu.2022.888713. View

15.

Zhang H, Wang X, Shen Z, Xu J, Qin J, Sun Y . Infiltration of diametrically polarized macrophages predicts overall survival of patients with gastric cancer after surgical resection. Gastric Cancer. 2014; 18(4):740-50. DOI: 10.1007/s10120-014-0422-7. View

16.

Graff J, Dickson A, Clay G, McCaffrey A, Wilson M . Identifying functional microRNAs in macrophages with polarized phenotypes. J Biol Chem. 2012; 287(26):21816-25. PMC: 3381144. DOI: 10.1074/jbc.M111.327031. View

17.

Boutilier A, Elsawa S . Macrophage Polarization States in the Tumor Microenvironment. Int J Mol Sci. 2021; 22(13). PMC: 8268869. DOI: 10.3390/ijms22136995. View

18.

Park S, Sun J, Choi Y, Oh D, Kim H, Lee T . Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study. ESMO Open. 2022; 7(1):100385. PMC: 8850741. DOI: 10.1016/j.esmoop.2022.100385. View

19.

Christofides A, Strauss L, Yeo A, Cao C, Charest A, Boussiotis V . The complex role of tumor-infiltrating macrophages. Nat Immunol. 2022; 23(8):1148-1156. PMC: 10754321. DOI: 10.1038/s41590-022-01267-2. View

20.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View